Curcumin to Prevent Complications After Elective Abdominal Aortic Aneurysm (AAA) Repair

Curcumin to Prevent Perioperative Complications After Elective Abdominal Aortic Aneurysm Repair: a Randomized Controlled Trial

Sponsors

Lead Sponsor: Lawson Health Research Institute

Collaborator: Canadian Institutes of Health Research (CIHR)

Source Lawson Health Research Institute
Brief Summary

The purpose of this program of research is to determine whether curcumin, a natural health product, can prevent acute kidney injury and other complications after elective AAA repair. If proven safe and effective, curcumin is an inexpensive intervention which can be readily applied to almost 50,000 AAA repairs performed worldwide each year. New knowledge about this intervention may also guide its use in other surgical and medical settings to prevent complications to the kidneys, heart and other organs.

Detailed Description

An abdominal aortic aneurysm (AAA) is a ballooning of the abdominal aorta, the major blood vessel of the body. AAA occurs in up to 2% of adults. Surgeons will plan an AAA repair when the aneurysm grows bigger than 5.5cm, because the AAA might burst without repair. Over 47,000 AAA repairs are performed each year. Despite the benefits of AAA repair there are risks, and the kidneys can be severely injured. We will test whether the natural health product curcumin has an effect on biomarkers of inflammation, kidney injury and heart injury from AAA repair. Curcumin appears to fight oxidation and inflammation, which are ways that the body can be injured by surgery. We will study 600 patients who have elective AAA repair. The patients will receive either curcumin or a matching placebo. We will recruit the 600 patients from 10 centres in Ontario. This study will help us determine whether curcumin exerts any biological effect on biomarkers and whether it is well tolerated. If there is evidence of beneficial effects in this 600 patient trial, this will justify a future larger trial to assess the effects of curcumin on outcomes most important to patients, families and their healthcare providers.

Overall Status Completed
Start Date November 2011
Completion Date August 2016
Primary Completion Date November 2014
Phase Phase 2/Phase 3
Study Type Interventional
Primary Outcome
Measure Time Frame
Urine IL-18 Post op value
NT-ProBNP Change in post-operative minus pre-operative plasma NT-Pro BNP
hsCRP Change in post-operative minus pre-operative plasma hsCRP
Serum creatinine Change in peak post-operative serum creatinine (umol/L) in the 7 days following AAA repair minus pre-op value
Secondary Outcome
Measure Time Frame
Binary measures of continuous biomarker outcomes Continuous
Safety outcomes Peri-operative period
Composite clinical outcomes adjudicated by investigators unaware of treatment outcomes Within 30 days of AA repair
Enrollment 606
Condition
Intervention

Intervention Type: Drug

Intervention Name: curcumin

Description: Patients will take the study medication (500 mg x 4 capsules, twice daily [BID]) for two days leading up to repair, totaling 4000 mg per day. They will take a dose (2000 mg) the morning of repair, at the same time as regular medications not held for surgery. While they are on call to the operating room, they will take another dose of 2000 mg and then another 2000 mg dose 6 hours after the repair. Final dose is administered the morning after repair.

Arm Group Label: curcumin

Other Name: NHPID name: curcumin

Intervention Type: Other

Intervention Name: placebo

Description: The placebo will look, smell, taste, and in every way be identical to the active drug. Patients will take the study medication in the exact same manner as the curcumin regimen.

Arm Group Label: placebo

Other Name: No brand name applicable.

Eligibility

Criteria:

Inclusion Criteria:

- Elective repair of an AAA (excludes thoracic or thoracoabdominal aneurysms)

- 18 years of age or older

- Able to provide informed consent

- Has one or more of the following criteria at time of preoperative assessment:

- x Open repair OR

- x Endovascular repair with ≥ 1 of the following criteria:

- o diabetes mellitus treated with insulin or oral hypoglycemic agents

- o age > 70 years

- o pre-existing renal impairment (baseline serum creatinine level >177 μmol/L for men or >146 μmol/L for women)

- If diabetic, is able and willing to collect and record glucose levels at home

Exclusion Criteria:

- emergent or urgent repair (repair < 3 days from pre-admission visit; ruptured AAA)

- prior renal transplantation

- pregnant or breastfeeding

- active gastrointestinal reflux disease, gastrointestinal ulcers or hepatobiliary disease (including gallstones)

- has active liver disease

- evidence of AKI (> 50% increase in serum creatinine) in the 30 days prior to repair

- enrolled in another randomized controlled trial

- receipt of ≥ 1 dialysis treatment in the past week

- previous participation in this trial

- repair is scheduled > 90 days from date of informed consent

- unable to provide written consent

- allergy(ies) to any member of the Zingiberaceae family: turmeric, ginger, curry, cumin, cardamom)

- allergy(ies) to ingredients of the study product or placebo: yellow or red food coloring, gelatin or cellulose

- have a history of major bleeding event in the previous 6 months

- bleeding disorders: a diagnosis of hemophilia, von Willebrand disease, platelets less than 70 for any reason

- history of hypoglycemia in the past 6 months: blood sugar less than or equal to 3.5 mmol/L

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Overall Official
Last Name Role Affiliation
Amit X Garg, MD, PhD Principal Investigator Lawson Health Research Institute
Location
Facility:
University of Calgary | Calgary, Alberta, T3B 6A8, Canada
University of Alberta Hospital | Edmonton, Alberta, T6G 2B7, Canada
St. Boniface Hospital | Winnipeg, Manitoba, R2H 2A6, Canada
Hamilton General Hospital | Hamilton, Ontario, L8L 2X2, Canada
London Health Sciences Centre | London, Ontario, N6G 5W9, Canada
The Ottawa Hospital, Civic Campus | Ottawa, Ontario, K1Y4E9, Canada
Sudbury Regional Hospital | Sudbury, Ontario, P3E5J1, Canada
Sunnybrook Health Sciences Centre | Toronto, Ontario, M4N3M5, Canada
St. Michael's Hospital | Toronto, Ontario, M5B1W8, Canada
Maisonneuve-Rosemont Hospital | Montreal, Quebec, H1T 2M4, Canada
Location Countries

Canada

Verification Date

March 2017

Responsible Party

Type: Principal Investigator

Investigator Affiliation: Lawson Health Research Institute

Investigator Full Name: Amit Garg

Investigator Title: Professor, Medicine, Epidemiology & Biostatistics

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Label: curcumin

Type: Experimental

Description: Patients will take the study medication (500 mg x 4 capsules, twice daily [BID]) for two days leading up to repair, totaling 4000 mg per day. They will take a dose (2000 mg) the morning of repair, at the same time as regular medications not held for surgery. While they are on call to the operating room, they will take another dose of 2000 mg., and then another 2000 mg dose 6 hours after the repair. Final dose (2000 mg)is administered morning after repair.

Label: placebo

Type: Placebo Comparator

Description: The placebo will look, smell, taste, and in every way be identical to the active drug. Patients will take the study medication in the exact same manner as the curcumin regimen.

Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Primary Purpose: Prevention

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Source: ClinicalTrials.gov